Leukemia

A new study confirms that patients with primary cutaneous diffuse large B-cell lymphoma who have a MYD88 mutation have a shorter disease-specific survival.

The addition of gemtuzumab-ozogamicin to standard chemo improved event-free survival in children and young adults with newly diagnosed acute myeloid leukemia.

Patients with pediatric BCR-ABL1-like acute lymphoblastic leukemia should be given risk-directed therapy based on minimal residual disease levels, according to a new study.

The FDA approved idelalisib (Zydelig) yesterday for the treatment of relapsed chronic lymphocytic leukemia (CLL), follicular B-cell non-Hodgkin lymphoma (FL), and small lymphocytic lymphoma (SLL).

Rapidly generated virus-specific T cells (VSTs) were safe and effective against five infections that commonly affect immunocompromised patients after marrow or stem cell transplantation, according to a new small study.

The FDA has granted breakthrough therapy designation to a novel treatment known as CTL019, a therapy intended for patients with relapsed/refractory acute lymphoblastic leukemia (ALL).

Is PCNSL resection safe? Evidence from clinical trials in which enrollment follows surgery-such as G-PCNSL-SG-1-is not valid proof of the safety of resection.

Relatively few patients with primary diffuse large B-cell lymphoma (PCNSL) will have tumors that are amenable to resection. In the absence of the highest quality data, at least it is good to know that in the modern era, patients with PCNSL are probably not harmed by judicious tumor resection.

For the practicing medical or neuro-oncologist, the treatment approach would currently not change, given that systemic therapy should be started as soon as the diagnosis of PCNSL is made and the patient is stable from a neurosurgical perspective. In most cases, one would not refer the patient back to the surgeon for additional debulking.

Lymphocyte infusions are extremely effective therapy in patients with chronic myeloid leukemia who relapse after allogeneic hematopoietic stem cell transplantation, and the timing of the infusion is relatively unimportant, according to a new study.

Long-term outcomes of patients treated for pediatric acute lymphoblastic leukemia (ALL) with modern treatment protocols are good, with an overall low risk for serious long-term side effects.

The FDA has approved the drug belinostat to treat patients with relapsed or refractory peripheral T-cell lymphoma.

Measuring changes in levels of BCR-ABL in patients with chronic myeloid leukemia (CML) can help predict treatment outcomes and disease progression, according to a new study.

Researchers have identified Down syndrome as a risk factor for infection-related mortality among pediatric patients with acute lymphoblastic leukemia.

A novel inhibitor of CD19 was well tolerated and showed promising activity in patients with relapsed or refractory B-lineage non-Hodgkin lymphoma, according to a phase I study.

A phase II trial of the selective spleen tyrosine kinase (Syk) inhibitor GS-9973 showed substantial biologic activity in patients with chronic lymphocytic leukemia (CLL).

Ibrutinib substantially increased progression-free survival and overall survival over ofatumumab in patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), according to the results of the RESONATE trial.

As part of our coverage of the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting, we discuss the pros and cons of follow-up imaging in lymphoma.

The new drug volasertib, which is in trials for the treatment of patients with acute myeloid leukemia (AML), has been granted orphan drug designation by the FDA.

Obesity or underweight status at diagnosis can influence outcomes in pediatric ALL patients, but a new study shows that the risk can be mitigated if weight status changes following treatment induction.

A novel agent known as BL-8040 will enter phase I/II testing for the treatment of chronic myeloid leukemia, according to BioLineRx, the company developing the drug.

A rare subtype of disease known as atypical chronic myeloid leukemia (aCML) has been shown to be clinically distinct from a related condition known as unclassifiable myelodysplastic/myeloproliferative neoplasm.

The FDA has approved siltuximab (Sylvant) for the treatment of multicentric Castleman disease, a disorder of the lymph nodes that is similar to lymphoma and often treated with chemotherapy and radiation.

Using both clinical and molecular markers, researchers have created a simple prognostic index for patients with cytogenetically normal acute myeloid leukemia (AML).